Mitotic progression of mammalian cells is tightly regulated by
Introduction
Duplicated chromosomes are attached to the mitotic spindles before segregating into two copies; this process is under tight control by a protein complex called anaphase promoting complex (APC) (1) . APC is an E3-ligase responsible for catalyzing the ubiquitination and eventual degradation of mitotic regulatory proteins, such as cyclin B1 and securin (1) . Once all the chromosomes are properly aligned and attached to the mitotic spindles, APC is activated by the coactivator Cdc20, which complexes with APC and functions as an adaptor for substrate recognition (1) . This will result in subsequent degradation of APC target proteins and initiation of chromosome segregation (1) . APC/Cdc20 is tightly regulated by the mitotic checkpoint proteins, i.e. Mad2 or BubR1, which bind to Cdc20 and inhibit APC from targeting its substrates (2) . This inhibition of APC/Cdc20 activity ensures that cells will not enter anaphase with unattached chromosomes and, as a result, prevents chromosome missegregation (3) . Accordingly, aberrant expression of mitotic checkpoint proteins has been found to induce chromosome instability and promote cancer development (3) .
During the late stage of mitosis, APC is activated by Cdh1, another coactivator that facilitates the onset of cytokinesis and mitotic exit by targeting a series of APC substrates (1) . Similar to APC/Cdc20, deregulation of APC/Cdh1 also plays an important role in chromosome instability and possibly attributes to cancer predisposition. Whereas complete knockout of Cdh1 caused embryonic lethality in vivo, Cdh1 heterozygous mice are prone to spontaneous tumor development (4) .
More interestingly, a number of APC/Cdh1 inhibitors have been demonstrated to induce chromosome instability in vitro. For example, Id-1, an oncoprotein involved in the carcinogenesis of prostate cancer, was shown to suppress APC/Cdh1 activity by disrupting the interaction between Cdh1 and APC (5) . Overexpression of Id-1 in human prostate epithelial cells induces polyploidy in the presence of the microtubule disrupting agents (5) . Meanwhile, overexpression of cyclin E, an activator of cyclin-dependent kinase 2, has also been shown to inhibit APC/Cdh1 and result in polyploidy (6) .
Daxx is a transcription repressor mainly localized in the promyelocytic leukemia protein (PML) nuclear body within the nucleus (7) . Previous study demonstrated that Daxx is associated with the chromatin-remodeling complex during S phase and may play a role in the reassembling of the heterochromatin at mitotic entry (8, 9) . Meanwhile, Daxx was found to bind to kinetochore-associated protein CENP-C (10), which is required for the kinetochore localization of mitotic checkpoint proteins during mitosis (11) . Knockout of Daxx has been found to increase the percentage of double-nuclei cells (12) . Furthermore, Daxx depletion has been shown to promote the survival of breast cancer cells upon treatment with a microtubule stabilization agent (13) , an effect that is similar to the silencing of mitotic checkpoint protein Mad2 (14) . These findings suggest that Daxx may be involved in the regulation of mitotic progression.
In this study, we show that Daxx functions as a novel inhibitor of APC. Daxx binds to APC coactivators Cdc20 and Cdh1 and inhibits the degradation of APC substrates during mitosis. Daxx level is frequently upregulated in prostate cancer cells and ectopic expression of it leads to chromosome missegregation in the non-malignant prostate epithelial cells. Our results suggest that Daxx may be involved in the regulation of mitotic progression by functioning as a novel APC inhibitor, and Daxx upregulation may be associated with prostate cancer development.
Materials and methods

Cell line and cell culture condition
Three human prostate cancer cell lines, LNCaP, PC-3 and DU145, the cervical cancer cell line HeLa and the HEK293FT cells were obtained from American Type Culture Collection (Rockville, MD). C42b and 22RV1 were gifts from Prof. Franky Chan (Department of Anatomy, Chinese University of Hong Kong). The osteosarcoma cancer cell line U2OS was a gift from Dr Y.P. Ching (Department of Anatomy, University of Hong Kong). The immortalized prostate epithelial cell line HPr-1 was established in our previous study (27) . All the prostate cancer cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum and penicillin/streptomycin. HEK293, HeLa and U2OS cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and penicillin/streptomycin. The immortalized prostate epithelial cell line HPr-1 was maintained in Keratinocytes-SFM (Invitrogen, Carlsbad, CA) and penicillin/streptomycin. All cells were kept at 37 o C in 5% CO 2 .
Cell synchronization was carried out using nocodazole block. Briefly, cells were first treated with 330 nM of nocodazole for 16 h. The rounded-up cells were harvested by shake-off and placed into fresh medium. The cells were then collected at different time points for western blotting or flow cytometry analysis.
Role of Daxx in the regulation of mitosis
Prof. Salmon (Department of Biology, University of North Carolina). All plasmids were transiently transfected into the cells, using the Fugene 6 reagent (Roche, Indianapolis, IN) following the protocol provided by the manufacturer.
Generation of stable Daxx transfectants
To generate stable transfectants overexpressing Daxx protein, full-length Daxx cDNA was first cloned into the pLenti6-V5-Topo vector (Invitrogen, Carlsbad, CA). The resulting plasmid was transfected into 293HT cells, and the lentivirus was used to infect the HPr-1 cells. Stable clones were selected using 6.5 µg/ml of blasticidine.
Site-directed mutagenesis
Daxx D-box mutants were generated by site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instruction. One hundred nanogram of wild-type pFlag-Daxx was used as template and 100 ng of each primer (Daxx D-box mutant 1: 5′ GCTGCCGGACACAGCATTGGCCTC-3′; Daxx D-box mutant 2: 5′-CTCCCCGGACAGCAGATCCAGCTCATG-3′; Daxx D-box mutant 3: 5′-CAGGAGGGACGTCACATCGATCTCATC-3′; Daxx D-box mutant 4: 5′-AAGAGAGGAGCTCGGATCCAAGGCACC-3′) were used for the four putative D-boxes mutation in the D-box region. The sequence of pFlag-Daxx D-box mutants were confirmed by DNA sequencing using 5′-aggttaacaggcgcattgag-3′ and 5′-actagggccctcaccagaat-3′ for 5′ and 3′ end, respectively.
Small interfering RNA
Small interfering RNA (siRNA) targeting Daxx, 5′-GGAGTTGGATCTCT CAGAAT -3′, and scramble RNA oligo were purchased from Dharmacon (Chicago, IL). Cells were seeded on a T25 flask at a confluency of 50% one day before transfection. siRNA was transfected into the cells using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA) following the manufacturer's instructions.
Analysis of APC/Cdc20 activity
The pGL3-D-box-Luc plasmid was a gift from Dr Jin (Department of Biochemistry, The University of Hong Kong). It was constructed by inserting the DNA fragment encoding the N-terminus (1-119 a.a.) of the human cyclin B protein into the pGL3-control vector. The resulting plasmid encodes a luciferase protein that was conjugated with the N-terminus (containing the D-box) of the cyclin B protein. Luciferase activities (Firefly) were measured, using the Dual Luciferase reporter assay kit (Promega, Madison, WI) and normalized with the internal control (Renilla). Each experiment was repeated in triplicate, and each data point represents a mean and standard deviation. Statistical difference was determined by Student's t-test and was considered significant at P < 0.05.
Western blotting
Experiments were carried out as described previously (28) . Briefly, whole-cell lysate was prepared by resuspending the cell pellet in RIPA buffer [50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP40, 0.5% deoxycholic acid and 0.1% sodium dodecyl sulfate], including protease inhibitors [1 mM Na 3 VO 4 , 1 µg/ ml aprotinin, 1 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride], and protein concentrations were measured using DC Protein Assay kit (Bio-Rad, Hercules, CA). Protein extract was resolved by electrophoresis and transferred to a polyvinylidene difluoride membrane (Amersham, Piscataway, NJ). The membrane was then incubated with primary antibodies against Daxx, securin, cyclin B1, c-myc, Cdc20, Aurora A, BubR1, β-actin (Santa Cruz Biotechnology, CA), Plk1 (Zymed, CA), Flag, HA (Sigma, MO), Mad2 and Cdc27 (BD Biosciences, CA) for 1-2 h at room temperature. After washing with Tris-buffered saline with -Tween, the membrane was incubated with secondary antibody against mouse, rabbit or goat IgG, and the signals were visualized using ECL Plus western blotting system (Amersham, Piscataway, NJ).
Flow cytometry analysis
Cells were fixed with 1 ml ice cold 70% ethanol and stored at 4 o C. After fixation, cell pellets were collected by centrifugation, resuspended with 500 μl phosphate-buffered saline and incubated at 4 o C a day before performing flow cytometry. The next day, cells were stained with propidium iodide (50 µg/ml) and RNase (1 µg/ml) for 30 min. Cell cycle analysis was performed on a flow cytometer EPICS profile analyzer and analyzed using the ModFit LT2.0 software (Coulter, Miami, FL).
Metaphase analysis
Metaphase cells were obtained by treating HPr-1 cells with nocodazole at a final concentration of 200 nM for 48 h. The cells were collected, treated with 0.8% sodium citrate for 15 min at 37 o C and then fixed in methanol/acetic acid in a ratio of 3:1. Cell suspension was dropped onto slides and dried. Chromosome number of at least 50 metaphase cells was counted under light microscopy with 400× magnification. Each experiment was repeated in triplicate, and each data point represents the mean and standard deviation. Statistical difference was determined by Student's t-test and was considered significant at P < 0.05.
Coimmunoprecipitation assay
Cells were lysed in RIPA buffer after transfected with different constructs. Cell lysate was first precleared with normal mouse IgG and protein G agarose for 1 h. Immunoprecipitation was then performed with agarose-conjugated anti-FLAG antibody or with anti-Cdc20 antibody. The mixture was incubated with gentle rocking overnight at 4 o C. The resin was then washed three times with lysis buffer. Immunoprecipitate pulled down by anti-Flag antibody was eluted with 3× Flag peptide (150 ng/ml) for 10 min at 4°C. For the immunoprecipitate pulled down by anti-Cdc20 (mouse) or anti-Daxx antibody (rabbit), the sample was boiled in 2× sample buffer for 10 min. The eluted complex was loaded onto sodium dodecyl sulfate-polyacrylamide gel for electrophoresis and western blotting analysis with the procedures described above.
Live cell imaging
HeLa cells were seeded onto glass bottom microwell dishes (MatTek Corporation, Ashland, MA), followed by transient transfections with the pDsRed-Daxx and the GFP-cdc20 plasmids. The transfected cells were synchronized with 2 mM thymidine for 16 h. The cultures were transferred to and maintained at 37°C/5% CO 2 , with a microincubator fitted to a microscope stage. Confocal images were taken at defined zoom (X40 Plan-neo DIC 1.3 N.A. objective), using a Zeiss Axiovert 200 M microscope with a Nipkow disk-based spinning confocal head (Ultraview ERS, Perkin Elmer, MA). Pictures were taken every 6 min for 20 h using the Ultraview acquisition software (Perkin Elmer, MA).
Immunohistochemistry study on prostate tissue array
Immunohistochemistry was carried out using the Avidin-Biotin Complex (ABC) Vectastain Kit (Vector Laboratories, Burlingame, CA), according to the manufacturer's instructions. Briefly, tissue microarray constructed in previous studies (29) were sectioned, deparaffinized and rehydrated using the standard protocol. The sections were then blocked with 0.3% H 2 O 2 in methanol for 20 min followed with normal serum at 37°C for 30 min. Sections were then incubated with anti-Daxx antibody and then with secondary antibody. Finally, the sections were incubated with avidin-biotin complex reagent before being stained with diaminobenzidine and counterstained with Mayer's hematoxylin. All of the stained sections were evaluated in a blinded manner without prior knowledge of the patient data. The intensity of all three cores of each sample was scored as low, moderate and high.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 software (SPSS Inc, Chicago, IL). Differences in Daxx expression among different histological groups of specimens were analyzed by the Mann-Whitney test. The correlation of Daxx expression level, with Gleason score or disease metastasis, was analyzed by Spearman's rank test. Data of the APC/Cdh1 assay were analyzed by t-test. For all tests, a P value < 0.05 was considered to be significant.
Results
Effect of Daxx knockdown on mitotic progression
To study the function of Daxx during mitosis, U2OS cells were transiently transfected with Daxx siRNA and then synchronized in mitosis by nocodazole treatment. As shown in Figure 1A , mitotic progression was similar between the scrambled and Daxx siRNA-transfected U2OS cells, except at 60 min post-nocodazole treatment, where a transient but significant increase in the G 1 population was detected in Daxx siRNA transfectants. This indicated that knockdown of Daxx resulted in a transient acceleration of mitotic progression. Interestingly, the cyclin B1 level was found to be much lower in Daxx siRNA transfectants when compared with the control ( Figure 1B) . One possible explanation for this observation would be that APC/Cdc20 is more active when Daxx has been knocked down. To test this hypothesis, we first examined if Daxx interacts with Cdc20. As shown in Figure 2A , immunoprecipitation of Flag-Daxx protein, using anti-Flag antibody, successfully pulled down HA-Cdc20 proteins, indicating that they physically interact with each other. The experiment was repeated using anti-HA antibody, which confirmed the interaction between the two proteins (data not shown).
To investigate if Daxx and Cdc20 colocalize during cell cycle progression, HeLa cells were cotransfected with plasmids expressing the DsRed-Daxx and pCS2-GFP-Cdc20. Images of cells during S phase, mitosis and the G 1 phase were taken with fluorescence microscope. As shown in Supplementary Figure 1A , available at Carcinogenesis Online, Daxx was found to colocalize with Cdc20 during S phase and mitosis. Similar to previous reports, Daxx was found to localize into several small, round-shaped structures within the nucleus at G 1 phase (Supplementary Figure 1B , available at Carcinogenesis Online), where these structures are likely to constitute the PML nuclear body (15) . In contrast, Cdc20 was undetectable at G 1 phase (Supplementary Figure 1A , available at Carcinogenesis Online), possibly due to protein degradation mediated by APC/Cdh1 (1).
To identify the Cdc20-binding domain within the Daxx protein, we subsequently mutated the two KEN boxes in the Daxx protein (Supplementary Figure 1B , available at Carcinogenesis Online) and repeated the experiment using these Daxx mutants. As shown in Figure 2B , the interaction between Daxx and Cdc20 was not affected by mutation at one or both KEN boxes. Meanwhile, Daxx mutants with deletion at these two KEN boxes can still bind to Cdc20 ( Figure 2C, lanes 4, 6 and 7) , suggesting that the two KEN boxes are dispensable for the interaction. However, mutation or deletion of the D-box sequences was found to completely abolish the interaction between the two proteins ( Figure 2B , bottom panel and 2C, lanes 5 and 8), indicating that Daxx binds to Cdc20 through the D-box sequences.
Daxx inhibits APC/Cdc20 activity
Because Daxx was found to interact with Cdc20 and downregulation of Daxx was shown to promote mitotic progression, it is possible that Daxx may function as a novel APC/Cdc20 inhibitor. To test this idea, cells were transfected with a plasmid expressing a fusion protein containing the D-box sequence of cyclin B1 conjugated to luciferase. This allowed us to indirectly determine APC/Cdc20 activity by measuring luciferase activity. As shown in Figure 3A , luciferase activity was significantly upregulated (~3-fold) in cells transfected with the Daxx expression vector, suggesting that Daxx may inhibit APC/Cdc20 activity, which leads to stabilization of the D-box-conjugated luciferase protein.
Meanwhile, deletion of the D-box sequences, which abolished the interaction between Daxx and Cdc20, was found to alter the inhibitory effect of Daxx on APC/Cdc20 activity ( Figure 3A) . This indicates that the binding of Daxx to Cdc20 is critical for regulating APC/Cdc20 function.
Mitotic checkpoint proteins, such as Mad2, inhibited APC/ Cdc20 activity by suppressing both the assembly of APC/Cdc20 and its substrate binding (16) . To study the mechanism responsible for the inhibition of APC/Cdc20 by Daxx, we first investigated the effect of Daxx knockdown on APC/Cdc20 assembly. APC/ Cdc20 complex formation was examined in HeLa cells at mitosis by immunoprecipitating with an anti-Cdc20 antibody. As shown in Figure 3B (upper panel), the interaction between Cdc20 and Cdc27, one of the components of the APC, was not affected by knockdown of Daxx. Instead, the binding of the two substrates cyclin B1 and securin to Cdc20 was significantly increased by knockdown of Daxx ( Figure 3B , lower panel), indicating that Daxx interfered with the substrate binding ability of Cdc20. Interestingly, Daxx was found to also interact with two mitotic checkpoint proteins, BubR1 and Mad2 ( Figure 3C ). Meanwhile, we found that knockdown of Daxx decreased the binding of Cdc20 to BubR1 but not to Mad2 ( Figure 3D ). These findings further support the idea that Daxx may function as a novel APC/Cdc20 inhibitor, possibly by facilitating the binding between BubR1 and Cdc20.
Effect of Daxx overexpression on mitotic progression
To further confirm the role of Daxx on mitotic progression, we also investigated the consequences of Daxx overexpression. As shown in Figure 4A , mitotic progression of HeLa cells was delayed by ectopic expression of Daxx. In addition, cyclin B1 and securin levels were also increased by Daxx expression ( Figure 4B ), confirming that Daxx delayed mitotic progression through the inhibition of APC/Cdc20-mediated cyclin B1 and securin degradation. Strikingly, in Daxx transfectants, levels of Aurora A and Plk1 were also found to be upregulated when compared with the vector control ( Figure 4B ), suggesting that Daxx also regulates APC/Cdh1 activity during mitosis. Meanwhile, coimmunoprecipitation assay confirmed that Daxx binds to Cdh1, although this interaction does not depends on the D-box sequences ( Figure 5A and B) .
To determine whether the binding of Daxx to Cdh1 is essential for regulating the activity of APC/Cdh1, we repeated the experiment in Figure 4 , using the Daxx mutant that does not bind to Cdh1 (DaxxΔ1-344). In agreement with the results in Figure 3 , ectopic expression of Daxx Δ1-344 did not affect the level of cyclin B1 and securin ( Figure 5C ). Furthermore, Daxx Δ1-344 also failed to affect the levels of Aurora A and Plk1 ( Figure 5C ), suggesting that disruption of the interaction between Daxx and Cdh1 abolished the inhibitory effect of Daxx on APC/Cdh1. 
Role of Daxx in the regulation of mitosis
Daxx is overexpressed in prostate cancer
Aberrant expression of APC inhibitors is frequently found in cancer cells and is believed to contribute to chromosome instability observed during cancer development (17, 18) . To test if Daxx also plays a role in prostate cancer development, we first compared the level of Daxx protein in five prostate cancer cell lines and a non-tumorigenic prostate epithelial cell line. As shown in Figure 6A , Daxx was detectable in all the cell lines, but the level was significantly elevated in all the cancer cell line when compared with the non-tumorigenic prostate epithelial cells (HPr-1), suggesting that Daxx overexpression may be associated with malignant transformation of prostate epithelial cells. We then examined the level of Daxx expression in prostate tissues from normal donors, patients with benign prostatic hyperplasia (BPH) or prostatic intraepithelial neoplasia (PIN), or from prostate cancer patients at primary or advanced stage. Figure 6B shows the representative results of the Daxx immunohistochemistry staining. In agreement with previous studies, positive Daxx staining was found to localize mainly within the nucleus of the cells ( Figure 6B, right panel) . Analysis of the staining intensity for all the specimens revealed that Daxx was expressed at low or undetectable levels only in the normal prostate tissues ( Figure 6C ). However, >90% of the prostate cancer tissues (49 of 55) were found to express moderate to high levels of Daxx protein, suggesting that Daxx is frequently overexpressed in prostate cancer cells ( Figure 6C) . Meanwhile, the level of Daxx expression was also found to be significantly correlated with both the tumor stage (P > 0.027, Figure 6C ) and disease metastasis (P > 0.032, Figure 6D) . These results further support the idea that Daxx may play roles in both the development and the progression of prostate cancer.
Daxx overexpression induced chromosome instability in prostate epithelial cells
To investigate the role of Daxx in prostate cancer development, we ectopically expressed Daxx in the non-malignant prostate epithelial cell line (HPr-1) ( Figure 7A ). Flow cytometry analysis revealed that the percentage of cells at G 1 phase was decreased in Daxx transfectants when compared with the empty vector control, which is consistent with the results observed in Daxx silencing ( Figure 1A) . Although in unsynchronized cells, Daxx overexpression did not affect the level of Aurora A or Plk1 ( Figure 7A ). In cells synchronized using nocodazole, upregulation of Plk1 was found in both Daxx transfectants ( Figure 7B ), confirming that Daxx can stabilize Plk1 in HPr-1 cells. However, we were unable to detect any difference in Aurora A protein level between the control and Daxx transfectants even after synchronization. More importantly, 48 h after nocodazole treatment, Daxx transfectants, but not the empty vector control, showed a significant increase in cells containing DNA content >4N ( Figure 7C) . In agreement, metaphase analysis revealed that the percentage of cell having abnormal chromosome number was also increased in cells overexpressing Daxx ( Figure 7D ). Taken together, these results suggest that ectopic Daxx expression can promote chromosome instability, possibly through aberrant inhibition of APC/Cdh1 during mitosis.
Discussion
Precise control of APC activity is crucial for maintaining the genomic integrity in mammalian cells, and deregulation of APC is frequently associated with chromosome instability and cancer predisposition (19) . In this study, we identified Daxx as a novel APC inhibitor frequently upregulated in prostate cancer.
Previous study revealed that knockout of Daxx leads to abnormal cytokinesis (12), although whether it plays a key role in mitotic progression is largely unknown. Our data suggest that Daxx not only physically binds to the Cdc20 and Cdh1 but also regulates their activities during mitotic progression. Cdc20 and Cdh1 are known to bind specifically to a consensus sequences, such as KEN or D-boxes, which are highly conserved among its substrates and regulators. This is also true for the Daxx protein that contains four D-box and three KEN box sequences. Surprisingly, only the D-boxes are crucial for mediating the interaction with Cdc20, whereas the Cdh1-interacting domain may lies within the amino acid 160-334. Recently, Daxx was found to interact with RASSF1A, which was found to be an APC/ Cdc20 inhibitor and substrate, with the binding domain being located at residues 290-740 (20) . It is thus possible that Daxx may be part of an APC inhibitory complex.
Our finding that Daxx interacts with Mad2 and BubR1 and inhibits APC/Cdc20 activity suggests that it probably plays a role in mitotic checkpoints. This is supported by the finding that Daxx depletion promotes the survival of breast cancer cells following treatment with microtubule stabilization agents (13) , an effect that is similar to the silencing of mitotic checkpoint protein Mad2 (14) . Meanwhile, Daxx has been identified as a direct binding partner of the kinetochore-associated protein CENP-C (10), which is required for the kinetochorelocalization of mitotic checkpoint proteins during mitosis (11) . More interestingly, truncation of the CENP-C binding region was found to abolish the inhibitory effect of Daxx on APC/Cdc20 (data not shown). Because we found that knockdown of Daxx reduce the interaction between Cdc20 and BubR1, it is reasonable to speculate that Daxx delays mitotic progression by promoting the assembly of the mitotic checkpoint complex. Giovinazzi et al. (20) recently demonstrated that addition of Daxx protein in vitro does not induce the activation of the APC/C. Meanwhile, they reported that knockdown of Daxx suppresses cyclin B1 protein level in mitotic cells and as a result accelerates mitotic progression (20) . It is not clear if the use of different cell lines (U2OS and Hela in this study and HEp2, a Hela-contaminated human epidermoid cancer cells in their study) may account for the discrepancy. Nevertheless, it would be worth to test whether Daxx overexpression on their system indeed produces an effect opposite to that by the shRNA-mediated Daxx knockdown.
An important question that needs to be addressed is how Daxx's function is regulated during the cell cycle. Unlike another APC/Cdc20 inhibitor, EMI1, which oscillates drastically during the cell cycle (21), the level of Daxx protein changed only slightly between different time courses (data not shown). However, Daxx protein has been shown to undergo a cell cycle-dependent translocation in previous studies (8, 15) . During late S phase, Daxx is released from PML to the heterochromatin, which then moves back to PML when the cell reached G 2 phase (8) . It leaves PML again at the entry of mitosis and does not relocate into the PML until the G 1 phase (15) . This pattern of cell cycle translocation seems to fit well with its inhibitory function on APC/Cdc20. Unlike APC/Cdc20, which is known to be regulated by the mitotic checkpoint, how APC/Cdh1 is regulated during late mitosis is still largely unknown. An in vitro study by Pfleger's group revealed that Mad2b inhibits the activity of APC/Cdh1 by blocking the release of substrates from the APC/Cdh1 complex (22) . Meanwhile, Id-1, an oncoprotein involved in multiple signaling pathways in tumorigenesis (23) , was also found to protect Aurora A and Cdc20 proteins from APC/Cdh1-mediated degradation. Similar to Mad2b and Id-1, overexpression of Daxx also stabilized these APC/Cdh1 substrates, indicating that Daxx may also function as a potential inhibitor of APC/Cdh1.
Many of the APC/Cdh1 inhibitors have been found to be overexpressed in cancer cells. These include EMI1 (multiple cancers) (17), Mad2b (colon cancer) (24) and Id-1 (multiple cancers) (23) . This is also true for Daxx, which we found to be upregulated in all the prostate cancer cell lines that we tested. Meanwhile, the expression of Daxx in prostate cancer tissue specimens was found to correlate with both tumor stage and disease metastasis, suggesting a positive role for Daxx in the development and progression of prostate cancer. Interestingly, as shown in HPr-1 cells, upregulation of Daxx alone is not sufficient for inducing chromosome instability. However, exposure of the Daxx transfectants to nocodazole was found to induce chromosome instability (Figure 7 ), which was accompanied by upregulation of the APC/Cdh1 substrate Plk1. Degradation of Plk1 is crucial for mitotic exit and aberrant expression of Plk1 was reported to induce cytokinesis failure and chromosome instability (25, 26) , supporting that stabilization of Plk1 by Daxx may contribute to chromosome instability and prostate carcinogenesis.
In conclusion, our results suggest for the first time that Daxx may function as a novel inhibitor of APC/Cdc20 and APC/Cdh1. Overexpression of Daxx, which was shown to affect mitotic checkpoint function and chromosome stability, is frequently detected in prostate cancer tissues and may contribute to prostate cancer development.
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